Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16874
Country/Region: Tanzania
Year: 2016
Main Partner: Tanzania Health Promotion Support
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $7,218,304 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $500,000
Care: TB/HIV (HVTB) $200,765
Care: Pediatric Care and Support (PDCS) $80,527
Testing: HIV Testing and Counseling (HVCT) $13,568
Sexual Prevention: Other Sexual Prevention (HVOP) $173,076
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $742,841
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $967,940
Treatment: Adult Treatment (HTXS) $4,129,575
Treatment: Pediatric Treatment (PDTX) $410,012
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 566
GEND_GBV Age/Sex: <10 Male 2017 515
GEND_GBV Age/Sex: 10-14 Female 2017 870
GEND_GBV Age/Sex: 10-14 Male 2017 637
GEND_GBV Age/Sex: 15-19 Female 2017 464
GEND_GBV Age/Sex: 15-19 male 2017 456
GEND_GBV Age/Sex: 20-24 Female 2017 357
GEND_GBV Age/Sex: 20-24 Male 2017 294
GEND_GBV Age/Sex: 25-49 Female 2017 454
GEND_GBV Age/Sex: 25-49 Male 2017 376
GEND_GBV Age/Sex: 50+ Female 2017 52
GEND_GBV Age/Sex: 50+ Male 2017 43
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 212
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 3,390
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 1,694
GEND_GBV Number of people receiving post-GBV care 2017 5,084
GEND_GBV Sum of Age/Sex Disaggregates 2017 2,588
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 55,240
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 56,177
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 248,464
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 93,294
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 453,175
HTS_TST Service Delivery Point (Community): Homebased testing 2017 564
HTS_TST Service Delivery Point (Community): Mobile testing 2017 844
HTS_TST Service Delivery Point (Facility): Inpatient 2017 18,552
HTS_TST Service Delivery Point (Facility): Other PITC 2017 16,599
HTS_TST Service Delivery Point (Facility): Outpatient 2017 194,549
HTS_TST Service Delivery Point (Facility): Pediatric 2017 108,608
HTS_TST Service Delivery Point (Facility): PMTCT 2017 113,459
HTS_TST Sum of Aggregated Age/Sex <15 2017 111,417
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 341,758
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 453,175
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 601
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 610
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 7,438
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 4,153
KP_MAT Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months 2017 1,326
KP_MAT Sex: Female 2017 438
KP_MAT Sex: Male 2017 888
KP_MAT Sum of Sex disaggregates 2017 1,326
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 2,001
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 437
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 888
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 648
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 3,974
KP_PREV Total estimated number of key population in the catchment area 2017 4,912
KP_PREV_den By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 2,354
KP_PREV_den By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area) 2017 515
KP_PREV_den By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area) 2017 1,045
KP_PREV_den By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area) 2017 998
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 52
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 52
LAB_PT CD4: Number of laboratories that perform this testing 2017 52
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 59
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 59
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 59
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 50
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 50
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 50
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 2
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 2
PMTCT_ART Already on ART at beginning of current pregnancy 2017 758
PMTCT_ART New on ART 2017 1,474
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 112,027
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 1,863
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 361
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 9
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 52
PMTCT_EID Sum of Infant Age disaggregates 2017 2,224
PMTCT_STAT By: Known positives at entry 2017 796
PMTCT_STAT By: Number of new positives identified 2017 1,544
PMTCT_STAT Number of new ANC and L&D clients 2017 117,930
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 112,027
PMTCT_STAT Sum of Positives Status disaggregates 2017 2,340
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 785
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 11
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 693
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 81
TB_SCREENDX Screen Result: Screened Positive for TB 2017 785
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 33,053
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 12,718
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 1,872
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 1,725
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 49,368
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,754
TX_CURR Aggregated Age/Sex: <15 Male 2017 1,991
TX_CURR Aggregated Age/Sex: 15+ Female 2017 33,118
TX_CURR Aggregated Age/Sex: 15+ Male 2017 15,102
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 51,965
TX_CURR Sum of Aggregated Age/Sex <15 2017 3,745
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 48,220
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 51,965
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 693
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 635
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 11,903
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 5,654
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 18,885
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 18,885
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 35,627
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 32,103
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 1,142
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 1,164
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 20,324
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 9,473
TX_PVLS Numerator: Indication: Routine 2017 17,028
TX_PVLS Numerator: Indication: Targeted 2017 15,075
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,264
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 1,281
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 22,564
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 10,518
TX_PVLS_den Denominator: Indication: Routine 2017 18,885
TX_PVLS_den Denominator: Indication: Targeted 2017 16,742
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 241
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 222
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,982
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,376
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 4,821
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 6,403
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 325
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 289
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,960
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,829
Cross Cutting Budget Categories and Known Amounts Total: $1,320,000
Human Resources for Health $700,000
Key Populations: MSM and TG $100,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs
Key Populations: Sex Workers $100,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Gender: Gender Based Violence (GBV) $170,000
GBV Prevention
Post GBV Care
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $250,000
Promoting gender-related policies and laws that increase legal protection